Literature DB >> 7823383

Serogroup C meningococcal outbreaks in the United States. An emerging threat.

L A Jackson1, A Schuchat, M W Reeves, J D Wenger.   

Abstract

OBJECTIVE: Multiple outbreaks of serogroup C Neisseria meningitidis have recently been reported from diverse areas of the United States. To better define the characteristics of this increasingly important problem, we reviewed data on all known serogroup C outbreaks in the United States from January 1980 through June 1993. DATA SOURCES: MEDLINE searches, Centers for Disease Control and Prevention records, state health department officials, infectious disease experts, and the meningococcal vaccine manufacturer. DEFINITION OF AN OUTBREAK: Three or more cases of serogroup C meningococcal disease within a 3-month period, either among members of a community or persons attending a single school or other institution, for which those cases represented an attack rate of at least five per 100,000 population.
RESULTS: Twenty-one outbreaks of serogroup C meningococcal disease were identified; eight occurred since 1991. In 1992 and the first half of 1993, approximately 180,000 doses of vaccine were administered for outbreak control, compared with approximately 34,000 doses from 1980 to 1991. Approximately 50% of community-outbreak cases were between the ages of 5 and 24 years, compared with only 19% of sporadic serogroup C cases (P < .001). Subtyping of patient isolates indicates that outbreaks are clonal; however, at least five distinct but closely related strains have caused recent outbreaks.
CONCLUSIONS: Serogroup C outbreaks are occurring more frequently in the United States. The effectiveness of preventive measures depends on early recognition; therefore, physicians should promptly report all cases of suspected meningococcal disease, and the causative serogroup should be established for every case.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7823383

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  55 in total

1.  Long-term persistence of a discotheque-associated invasive Neisseria meningitidis group C strain as proven by pulsed-field gel electrophoresis and porA gene sequencing.

Authors:  K Riesbeck; P Orvelid-Mölling; H Fredlund; P Olcén
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

3.  Characterization and acceptor preference of a soluble meningococcal group C polysialyltransferase.

Authors:  Dwight C Peterson; Gayathri Arakere; Justine Vionnet; Pumtiwitt C McCarthy; Willie F Vann
Journal:  J Bacteriol       Date:  2011-01-28       Impact factor: 3.490

4.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

5.  Molecular epidemiological analysis of the changing nature of a meningococcal outbreak following a vaccination campaign.

Authors:  Liran I Shlush; Doron M Behar; Adrian Zelazny; Nathy Keller; James R Lupski; Arthur L Beaudet; Dani Bercovich
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

6.  Genetic and antigenic analysis of invasive serogroup C Neisseria meningitidis in Canada: A decrease in the electrophoretic type (ET)-15 clonal type and an increase in the proportion of isolates belonging to the ET-37 (but not ET-15) clonal type during the period from 2002 to 2009.

Authors:  Jianwei Zhou; Frances Jamieson; Sharon Dolman; Linda Mn Hoang; Prasad Rawte; Raymond Sw Tsang
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

7.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

8.  First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.

Authors:  Lucy A McNamara; Alice M Shumate; Peter Johnsen; Jessica R MacNeil; Manisha Patel; Tina Bhavsar; Amanda C Cohn; Jill Dinitz-Sklar; Jonathan Duffy; Janet Finnie; Denise Garon; Robert Hary; Fang Hu; Hajime Kamiya; Hye-Joo Kim; John Kolligian; Janet Neglia; Judith Oakley; Jacqueline Wagner; Kathy Wagner; Xin Wang; Yon Yu; Barbara Montana; Christina Tan; Robin Izzo; Thomas A Clark
Journal:  Pediatrics       Date:  2015-05       Impact factor: 7.124

9.  Epidemiologic characteristics of an outbreak of serogroup C meningococcal disease and the public health response.

Authors:  P Houck; M Patnode; R Atwood; K Powell
Journal:  Public Health Rep       Date:  1995 May-Jun       Impact factor: 2.792

Review 10.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.